Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.

Morgan RD, Porter C, Zhou C, Kristeleit R, Desai S, Vazquez I, George A, Eminowicz G, Walther A, Franklin A, Sadozye AH, Hughes A, Hanna L, Roux R, Lord R, Bowen R, Wood J, Sentamans C, White A, Casbard AC, Humphrys A, Swettenham JB, Nixon LS, Adams R, Ray R, Brogden E, Powell WE, Canham J, Cox TM, Narasimham M, Lowe H, Ensell L, Zubair M, Morris K, Glenister-Doyle M, Gassio AF, Morgan D, Broughton D, Carucci M, Monaghan PJ, Tugwood J, Edmondson RJ, Dive C, Jayson GC, Clamp AR

Open source

DOI
10.1016/j.eclinm.2026.104012
Published
2026 Jun
Container
EClinicalMedicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2026.104012,
  title = {Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.},
  author = {Morgan RD and Porter C and Zhou C and Kristeleit R and Desai S and Vazquez I and George A and Eminowicz G and Walther A and Franklin A and Sadozye AH and Hughes A and Hanna L and Roux R and Lord R and Bowen R and Wood J and Sentamans C and White A and Casbard AC and Humphrys A and Swettenham JB and Nixon LS and Adams R and Ray R and Brogden E and Powell WE and Canham J and Cox TM and Narasimham M and Lowe H and Ensell L and Zubair M and Morris K and Glenister-Doyle M and Gassio AF and Morgan D and Broughton D and Carucci M and Monaghan PJ and Tugwood J and Edmondson RJ and Dive C and Jayson GC and Clamp AR},
  year = {2026},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2026.104012},
  url = {https://doi.org/10.1016/j.eclinm.2026.104012}
}

RIS

TY  - JOUR
TI  - Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.
AU  - Morgan RD
AU  - Porter C
AU  - Zhou C
AU  - Kristeleit R
AU  - Desai S
AU  - Vazquez I
AU  - George A
AU  - Eminowicz G
AU  - Walther A
AU  - Franklin A
AU  - Sadozye AH
AU  - Hughes A
AU  - Hanna L
AU  - Roux R
AU  - Lord R
AU  - Bowen R
AU  - Wood J
AU  - Sentamans C
AU  - White A
AU  - Casbard AC
AU  - Humphrys A
AU  - Swettenham JB
AU  - Nixon LS
AU  - Adams R
AU  - Ray R
AU  - Brogden E
AU  - Powell WE
AU  - Canham J
AU  - Cox TM
AU  - Narasimham M
AU  - Lowe H
AU  - Ensell L
AU  - Zubair M
AU  - Morris K
AU  - Glenister-Doyle M
AU  - Gassio AF
AU  - Morgan D
AU  - Broughton D
AU  - Carucci M
AU  - Monaghan PJ
AU  - Tugwood J
AU  - Edmondson RJ
AU  - Dive C
AU  - Jayson GC
AU  - Clamp AR
PY  - 2026
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2026.104012
UR  - https://doi.org/10.1016/j.eclinm.2026.104012
ER  -

APA

RD, M., C, P., C, Z., R, K., S, D., I, V., A, G., G, E., A, W., A, F., AH, S., A, H., L, H., R, R., R, L., R, B., J, W., C, S., A, W., AC, C., A, H., JB, S., LS, N., R, A., R, R., E, B., WE, P., J, C., TM, C., M, N., H, L., L, E., M, Z., K, M., M, G., AF, G., D, M., D, B., M, C., PJ, M., J, T., RJ, E., C, D., GC, J., & AR, C. (2026). Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.104012

Source records